

Hanif Esmail

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4444401/hanif-esmail-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29
papers

765
citations

14
h-index

27
g-index

32
ext. papers

1,084
ext. citations

18.4
avg, IF

4.33
L-index

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 29 | Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[F]fluoro-D-glucose positron emission and computed tomography. <i>Nature Medicine</i> , 2016 , 22, 1090-1093 | 50.5 | 120 |
| 28 | Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2015 , 3, 190-200 | 35.1 | 88 |
| 27 | Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. <i>Drug Discovery Today</i> , 2012 , 17, 514-21 | 8.8 | 68 |
| 26 | Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 395-406 | 35.1 | 63 |
| 25 | Complement pathway gene activation and rising circulating immune complexes characterize early disease in HIV-associated tuberculosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E964-E973 | 11.5 | 56 |
| 24 | The Immune Response to Mycobacterium tuberculosis in HIV-1-Coinfected Persons. <i>Annual Review of Immunology</i> , 2018 , 36, 603-638 | 34.7 | 52 |
| 23 | Tuberculosis Infectiousness and Host Susceptibility. <i>Journal of Infectious Diseases</i> , 2017 , 216, S636-S643 | 7 | 46 |
| 22 | The Wonder Years: What Can Primary School Children Teach Us About Immunity to ?. <i>Frontiers in Immunology</i> , 2018 , 9, 2946 | 8.4 | 36 |
| 21 | Tuberculosis is changing. <i>Lancet Infectious Diseases</i> , 2017 , 17, 359-361 | 25.5 | 35 |
| 20 | Subclinical Tuberculosis Disease-A Review and Analysis of Prevalence Surveys to Inform Definitions, Burden, Associations, and Screening Methodology. <i>Clinical Infectious Diseases</i> , 2021 , 73, e830-e841 | 11.6 | 35 |
| 19 | Detection and treatment of subclinical tuberculosis. <i>Tuberculosis</i> , 2012 , 92, 447-52 | 2.6 | 30 |
| 18 | From latent to patent: rethinking prediction of tuberculosis. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 243-244 | 35.1 | 21 |
| 17 | Tuberculosis transmission during the subclinical period: could unrelated cough play a part?. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 244-246 | 35.1 | 19 |
| 16 | Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations. <i>European Respiratory Journal</i> , 2020 , 55, | 13.6 | 18 |
| 15 | Screening for tuberculosis: time to move beyond symptoms. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 202-204 | 35.1 | 14 |
| 14 | Is MRSA admission bacteraemia community-acquired? A case control study. <i>Journal of Infection</i> , 2008 , 56, 163-70 | 18.9 | 12 |
| 13 | Spotting the old foe-revisiting the case definition for TB. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 199-201 | 35.1 | 10 |

| | | | |
|----|---|------|---|
| 12 | Short durations of corticosteroids for hospitalised COVID-19 patients are associated with a high readmission rate. <i>Journal of Infection</i> , 2021 , 82, 276-316 | 18.9 | 9 |
| 11 | QuantiFERON conversion following tuberculin administration is common in HIV infection and relates to baseline response. <i>BMC Infectious Diseases</i> , 2016 , 16, 545 | 4 | 6 |
| 10 | Recent progress in understanding immune activation in the pathogenesis in HIV-tuberculosis co-infection. <i>Current Opinion in HIV and AIDS</i> , 2018 , 13, 455-461 | 4.2 | 6 |
| 9 | Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings. <i>F1000Research</i> , 2020 , 9, 1109 | 3.6 | 3 |
| 8 | Individualising therapy for drug-sensitive tuberculosis. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 834-835 | 35.1 | 2 |
| 7 | Elevated N-terminal prohormone of brain natriuretic peptide among persons living with HIV in a South African peri-urban township. <i>ESC Heart Failure</i> , 2020 , 7, 3246-3251 | 3.7 | 2 |
| 6 | Cardio-Thoracic Ratio Is Stable, Reproducible and Has Potential as a Screening Tool for HIV-1 Related Cardiac Disorders in Resource Poor Settings. <i>PLoS ONE</i> , 2016 , 11, e0163490 | 3.7 | 2 |
| 5 | Mind the gap - Managing tuberculosis across the disease spectrum.. <i>EBioMedicine</i> , 2022 , 103928 | 8.8 | 2 |
| 4 | A threat to decentralised care for drug-resistant tuberculosis. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 950-952 | 35.1 | 1 |
| 3 | Tuberculosis prevalence: beyond the tip of the iceberg. <i>Lancet Respiratory Medicine</i> , 2022 , 10, 537-539 | 35.1 | 0 |
| 2 | Exploring a combined biomarker for tuberculosis treatment response: protocol for a prospective observational cohort study. <i>BMJ Open</i> , 2021 , 11, e052885 | 3 | |
| 1 | Before the whistle blows: developing new paradigms in tuberculosis screening to maximise benefit and minimise harm. <i>Wellcome Open Research</i> , 2021 , 6, 8 | 4.8 | |